Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Aleigha Lawless et al.|EClinicalMedicine|2023Cited by 26
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG. Saturno, Caroline J. Springer, Filipa M. Lopes et al.|Annals of Oncology|2020Cited by 21
Brain microenvironment-driven resistance to immune and targeted therapies in acral melanomaRebecca Lee, Richard Marais|ESMO Open|2020Cited by 6